Study guide

26.1 Radioisotopes, Radiopharmaceuticals & Gamma Camera / SPECT Operation

Philippine Radiologic Technologists Licensure Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Subject 1, Chapter 1: Physics of Radiology & X-Ray Production

1.1 Atomic Structure, Electromagnetic Spectrum & X-Ray Production Mechanisms 1.2 X-Ray Tube Components, Target Interactions & Emission Spectrum 1.3 Photon Interactions with Matter: Photoelectric, Compton, Coherent & Pair Production

2 Subject 1, Chapter 2: Radiographic Equipment & Circuitry

2.1 High-Voltage Generators, Transformers & Rectification Circuits 2.2 Automatic Exposure Control (AEC), Beam Restriction & Quality Control 2.3 Tube Rating Charts, Extending Tube Life, Mechanical Malfunction & Preventive Maintenance

3 Subject 1, Chapter 3: Radiobiology & Cellular Response

3.1 Radiation Interaction with Tissue, Direct/Indirect Action & LET/RBE 3.2 Law of Bergonie & Tribondeau, Deterministic vs. Stochastic Effects 3.3 Dose-Response Relationships, Embryo and Fetal Effects & Acute Radiation Syndrome

4 Subject 1, Chapter 4: Radiation Protection & Dose Limits

4.1 ALARA Principles, Structural Shielding & Dose Limits 4.2 Personnel Dosimetry & Patient Dose Reduction Techniques 4.3 Dose Calculation Problems: Time, Distance, Shielding & Structural Barrier Design

5 Subject 1, Chapter 5: Imaging Informatics & Quality Assurance

5.1 PACS Architecture, DICOM Standards & HL7 Integration 5.2 Quality Assurance & Quality Control Protocols in Diagnostic Radiography 5.3 Radiology Workflow, RIS/HIS Integration, Teleradiology & Informatics Quality Assurance

6 Subject 2, Chapter 6: Film-Screen Radiography & Sensitometry

6.1 Film Emulsion, Latent Image Formation & Darkroom Chemistry 6.2 Sensitometric Curve (H&D Curve), Film Speed & Contrast Characteristics 6.3 Radiographic Film Analysis: Processing Faults, Handling Artifacts & Corrective Measures

7 Subject 2, Chapter 7: Technical Factors & Radiographic Quality

7.1 Density/Brightness, Contrast, Spatial Resolution & Distortion Controls 7.2 Exposure Math: Inverse Square Law, 15% Rule & Grid Conversion Factors 7.3 Technique Compensation: Age, Pathology, Cast and Orthopaedic Devices, Screen Speed & Beam Restriction

8 Subject 2, Chapter 8: Computed Radiography (CR)

8.1 Photostimulable Phosphor (PSP) Plates & CR Reader Mechanics 8.2 Image Processing, CR Artifacts & Erasure Protocols

9 Subject 2, Chapter 9: Digital Radiography (DR)

9.1 Flat-Panel Detectors: Direct vs. Indirect Conversion & TFT Arrays 9.2 Detective Quantum Efficiency (DQE), Modulation Transfer Function (MTF) & Dynamic Range

10 Subject 2, Chapter 10: Exposure Indicators & Image Evaluation

10.1 Exposure Indicators (S-Number, EI, DI), Windowing & Look-Up Tables (LUT) 10.2 Image Critique Checklist, Artifact Identification & Quality Control Standards 10.3 Image Display & Hard-Copy Output: Monitor Classification, DICOM GSDF, Dry vs Wet Laser Imaging

11 Subject 3, Chapter 11: Chest, Abdomen & Routine Positioning Concepts

11.1 Anatomical Terminology, Body Planes & Chest Radiography (PA, Lateral, Decubitus) 11.2 Abdominal Radiography: Acute Abdomen Series & Erect/Supine Protocols 11.3 Radiologic Surface Anatomy, Body Habitus & Sectional Body Cuts

12 Subject 3, Chapter 12: Upper & Lower Extremities & Girdles

12.1 Upper Limb & Shoulder Girdle Positioning (Hand, Wrist, Forearm, Elbow, Humerus, Shoulder) 12.2 Lower Limb & Pelvic Girdle Positioning (Foot, Ankle, Leg, Knee, Femur, Pelvis, Hip)

13 Subject 3, Chapter 13: Spine & Bony Thorax

13.1 Cervical, Thoracic & Lumbar Spine Radiography & Trauma Adaptations 13.2 Sacrum, Coccyx, Sacroiliac Joints & Bony Thorax (Ribs & Sternum)

14 Subject 3, Chapter 14: Cranium, Facial Bones & Paranasal Sinuses

14.1 Skull Positioning: Towne, Caldwell, Lateral & SMV Projections 14.2 Facial Bones, Orbits, Zygomatic Arches & Paranasal Sinuses

15 Subject 3, Chapter 15: Contrast Media Studies & Special Procedures

15.1 Gastrointestinal Contrast Procedures (Esophagram, UGI, Small Bowel, Barium Enema) 15.2 Genitourinary, Biliary & Special Fluoroscopic Studies (IVU, Cystography, ERCP, Myelography) 15.3 Reproductive System Studies: Hysterosalpingography, Pelvimetry & Male Reproductive Procedures 15.4 Nasopharyngography, Sialography & Fistulography / Sinus Tract Visualization

16 Subject 4, Chapter 16: Human Anatomy, Physiology & Pathology Integration

16.1 Body System Anatomy & Systemic Physiology Overview for Radiographers 16.2 Radiologic Pathology: Image Manifestations of Neoplastic, Inflammatory & Traumatic Conditions

17 Subject 4, Chapter 17: Patient Assessment, Communication & Informed Consent

17.1 Professional Communication, History Taking & Patient Rights 17.2 Informed Consent, Medical Documentation & Patient Transfer Safety

18 Subject 4, Chapter 18: Infection Control & Vital Signs Monitoring

18.1 Standard Precautions, Asepsis, Sterilization & Isolation Protocols 18.2 Measurement & Assessment of Vital Signs (BP, Pulse, Respiration, Temperature)

19 Subject 4, Chapter 19: Emergency Care & Aseptic Venipuncture

19.1 Basic Life Support (BLS), CPR Concepts & Emergency Response in Radiology 19.2 Aseptic Venipuncture Technique, IV Maintenance & Extravasation Care

20 Subject 4, Chapter 20: Professional Ethics, Jurisprudence & RA 7431

20.1 Republic Act No. 7431 (Radiologic Technology Act of 1992) & Board Rules 20.2 Code of Professional Ethics, Legal Liabilities, Malpractice & Negligence 20.3 Bioethical Principles in Practice, Professional Virtues & Interprofessional Relationships

21 Subject 5, Chapter 21: Diagnostic Ultrasonography

21.1 Ultrasound Physics, Transducer Construction & Doppler Principles 21.2 Acoustic Artifacts, Clinical Applications & Safety (TI/MI) 21.3 Clinical Ultrasound Examinations: Indications, Patient Preparation, Scanning Protocols & Transducer Selection

22 Subject 5, Chapter 22: Computed Tomography (CT)

22.1 CT Physics, Gantry Components, Detectors & Helical/Multislice Acquisition 22.2 Hounsfield Units, Windowing, CT Artifacts & Radiation Dose (CTDI/DLP)

23 Subject 5, Chapter 23: Magnetic Resonance Imaging (MRI)

23.1 MRI Physics, Nuclear Spin, T1/T2 Relaxation & Pulse Sequences 23.2 MRI Safety (Zones I-IV, SAR, Metallic Implants) & Common Artifacts 23.3 MRI Examination Protocols, Patient Preparation, Gadolinium Contrast & Sectional MRI Anatomy

24 Subject 5, Chapter 24: Interventional Radiology & Vascular Imaging

24.1 Vascular Access, Seldinger Technique & Digital Subtraction Angiography (DSA) 24.2 Interventional Procedures (Embolization, Angioplasty, Stenting) & C-Arm Radiation Safety 24.3 Interventional Patient Management: Contrast Selection, Pre-Procedure Workup & Post-Procedure Care

25 Subject 5, Chapter 25: Contrast Media Pharmacology & Adverse Reactions

25.1 Classification of Contrast Agents: Osmolality, Viscosity & Iodine Concentration 25.2 Adverse Contrast Reactions (Mild, Moderate, Severe) & Emergency Treatment Protocols 25.3 General Pharmacologic Principles: Pharmacokinetics, Pharmacodynamics, Drug Categories & the Rights of Drug Safety

26 Subject 5, Chapter 26: Nuclear Medicine & Molecular Imaging

26.1 Radioisotopes, Radiopharmaceuticals & Gamma Camera / SPECT Operation 26.2 Positron Emission Tomography (PET/CT) & Unsealed Radiation Source Safety

27 Subject 5, Chapter 27: Radiation Therapy & Radiation Oncology

27.1 Principles of Radiation Oncology, Linear Accelerators & Treatment Planning 27.2 Teletherapy vs. Brachytherapy, Patient Immobilization & Side Effect Management 27.3 Isodose Planning, Treatment Delivery Methods & Radiobiologic Principles in Radiation Therapy

28 Mammography & Dental Radiography

28.1 Mammography: Equipment, CC and MLO Positioning, Compression & Breast Pathology 28.2 Dental Radiography: Paralleling and Bisecting Techniques, Bitewing, Occlusal, Panoramic & Cephalometric

29 Medical Terminology for Radiologic Technology

29.1 Medical Word Building: Root Words, Combining Forms, Prefixes & Suffixes 29.2 Medical Terms in General Medicine, Abbreviations, Symbols & Critiquing Requests and Reports

30 Radiology Administration, Organization & Leadership

30.1 Organizational Structure, Staffing & Licensing Requirements of a Radiology Facility 30.2 Radiology Department Management: Job Descriptions, Duties, Leadership Styles & Entrepreneurial Skills

26.1 Radioisotopes, Radiopharmaceuticals & Gamma Camera / SPECT Operation

Key Takeaways Explain This Topic AI

Technetium-99m (99mTc) is the primary diagnostic radionuclide in nuclear medicine due to its ideal 6.01-hour physical half-life, pure 140 keV monoenergetic gamma emission matching NaI(Tl) crystal peak efficiency, and absence of particulate beta radiation.

The Molybdenum-99 / Technetium-99m generator system operates under transient equilibrium (parent T1/2 = 66 h vs. daughter T1/2 = 6.01 h) and requires strict quality control testing for Mo-99 breakthrough (<0.15 uCi Mo-99 per mCi Tc-99m) and alumina contamination (<10 ug Al3+ per mL).

The Anger Gamma Camera utilizes lead collimators to define spatial origin, a thallium-doped Sodium Iodide NaI(Tl) scintillation crystal to convert gamma rays to 415 nm blue light, PMT arrays for X/Y spatial positioning, and a Pulse Height Analyzer (PHA) set to a 20% window (140 keV ± 10%) to reject Compton scatter.

Radiopharmaceuticals exhibit target-organ affinity based on physiological pathways: Tc-99m MDP binds hydroxyapatite in active bone turnover, Tc-99m Sestamibi accumulates in myocardial mitochondria for perfusion, and Tc-99m HMPAO crosses the blood-brain barrier for cerebral blood flow evaluation.

Single Photon Emission Computed Tomography (SPECT) rotates gamma camera heads 360 degrees around the patient to reconstruct 3D cross-sectional tomographic slices (FBP or OSEM), while hybrid SPECT/CT integrates high-resolution CT for precise anatomical localization and CT-based attenuation correction (CT-AC).

Last updated: August 2026

  • 26.1 Radioisotopes, Radiopharmaceuticals & Gamma Camera / SPECT Operation
  • Introduction to Nuclear Medicine Principles

Unlike structural diagnostic imaging modalities (such as conventional projection radiography and computed tomography) which measure differential X-ray beam attenuation through anatomical structures, Nuclear Medicine is a functional imaging modality. Radiopharmaceuticals—chemical compounds tagged with radioactive isotopes—are introduced into the human body (via intravenous injection, oral ingestion, or inhalation) to evaluate physiology, metabolism, organ perfusion, and cellular biochemistry.

The radiologic technologist (RadTech) specializing in nuclear medicine must master the physical principles of radioactive decay, radionuclide generator operation, radiopharmaceutical synthesis, gamma camera instrumentation, and cross-sectional SPECT/CT reconstruction.

Radioisotopes & Radioactive Decay Modes

Radionuclides are unstable atomic nuclei containing an excess of mass or energy that undergo spontaneous transformation ( radioactive decay ) to attain nuclear stability, emitting particulate or electromagnetic radiation in the process. +-------------------------------------------------------------------------+

  • | RADIOACTIVE DECAY MODES |
  • +-------------------+-------------------+-------------------+-------------+
  • | ALPHA (a) | BETA MINUS (b-) | BETA PLUS (b+) | GAMMA (g) |
  • | - He-4 nucleus | - Neutron -> p+ | - Proton -> n | - Isomeric |
  • | - High LET | - Emits e- + v_ | - Emits e+ + v | Transition|
  • | - Non-penetrate | - Therapy use | - PET imaging | - Pure photon|
  • | - High hazard | - e.g., I-131 | - e.g., F-18 | - Tc-99m |
  • +-------------------+-------------------+-------------------+-------------+
  • 1. Primary Modes of Nuclear Decay

Alpha Decay ( α \alpha α ) : Emission of a helium nucleus ( 2 4 He ^4_2\text{He} 2 4 ​ He , comprising 2 protons and 2 neutrons). Alpha particles possess high Linear Energy Transfer (LET) and high mass, penetrating only a few micrometers in soft tissue ( < 100 μ m <100 \ \mu\text{m} < 100 μ m ). Alpha emitters (e.g., Radium-223) cause severe localized double-strand DNA damage and are restricted strictly to targeted radionuclide therapy, never diagnostic imaging.

Beta-Minus Decay ( β − \beta^- β − ) : Occurs in neutron-rich nuclei. A neutron transforms into a proton, emitting a high-speed electron (negatron, e − \text{e}^- e − ) and an antineutrino ( ν ˉ \bar{\nu} ν ˉ ): n → p + + e − + ν ˉ \text{n} \rightarrow \text{p}^+ + \text{e}^- + \bar{\nu} n → p + + e − + ν ˉ Beta-minus particles penetrate several millimeters into tissue. While β − \beta^- β − emitters are widely used in therapy (e.g., Iodine-131 for thyroid ablation, Strontium-89 for bone pain palliation), their continuous bremsstrahlung and tissue ionizations create unnecessary patient radiation dose, making pure β − \beta^- β − emitters unsuitable for diagnostic gamma camera imaging.

Beta-Plus Decay ( β + \beta^+ β + / Positron Emission) : Occurs in proton-rich nuclei. A proton transforms into a neutron, emitting a positron (anti-electron, e + \text{e}^+ e + ) and a neutrino ( ν \nu ν ): p + → n + e + + ν \text{p}^+ \rightarrow \text{n} + \text{e}^+ + \nu p + → n + e + + ν The emitted positron travels a short distance ( 0.5 to 2.0 mm 0.5 \text{ to } 2.0 \text{ mm} 0.5 to 2.0 mm ) before annihilating with an electron, producing two 511 keV 511 \ \text{keV} 511 keV gamma photons used in PET imaging.

Gamma Decay ( γ \gamma γ ) & Isomeric Transition (IT) : Following particle emission, a daughter nucleus often remains in an excited nuclear energy state (metastable state, designated by 'm'). The nucleus transitions to its ground state by emitting pure electromagnetic energy in the form of a gamma photon ( γ \gamma γ ) without changing its atomic number ( Z Z Z ) or mass number ( A A A ): 43 99 m Tc → 43 99 Tc + γ ( 140 keV ) ^{99m}_{43}\text{Tc} \rightarrow ^{99}_{43}\text{Tc} + \gamma \ (140 \ \text{keV}) 43 99 m ​ Tc → 43 99 ​ Tc + γ ( 140 keV ) Isomeric transition is the ideal decay mode for diagnostic imaging because gamma photons readily exit the body to reach external detectors without causing high local tissue ionization.

Electron Capture (EC) : A proton-rich nucleus captures an inner-shell electron (usually K-shell), transforming a proton into a neutron ( p + + e − → n + ν p^+ + e^- \rightarrow n + \nu p + + e − → n + ν ). The resulting orbital vacancy is filled by an outer-shell electron, emitting characteristic X-rays or Auger electrons (e.g., Iodine-123, Thallium-201, Gallium-67).

2. Radioactive Decay Kinetics & Half-Life Equations

The rate of decay of a radioactive sample is its Activity ( A A A ), measured in Becquerels ( 1 Bq = 1 disintegration/second 1 \ \text{Bq} = 1 \ \text{disintegration/second} 1 Bq = 1 disintegration/second ) or Curies ( 1 Ci = 3.7 × 10 10 Bq = 37 GBq 1 \ \text{Ci} = 3.7 \times 10^{10} \ \text{Bq} = 37 \ \text{GBq} 1 Ci = 3.7 × 1 0 10 Bq = 37 GBq ).

Physical Half-Life ( T 1 / 2 T_{1/2} T 1/2 ​ or T p T_p T p ​ ) : The time required for a radioactive sample to decay to exactly 50 % 50\% 50% of its initial activity: A ( t ) = A 0 e − λ t = A 0 ( 1 2 ) t T 1 / 2 A(t) = A_0 e^{-\lambda t} = A_0 \left(\frac{1}{2}\right)^{\frac{t}{T_{1/2}}} A ( t ) = A 0 ​ e − λ t = A 0 ​ ( 2 1 ​ ) T 1/2 ​ t ​

Decay Constant ( λ \lambda λ ) : The fractional rate of decay per unit time: λ = ln ⁡ ( 2 ) T 1 / 2 = 0.693 T 1 / 2 \lambda = \frac{\ln(2)}{T_{1/2}} = \frac{0.693}{T_{1/2}} λ = T 1/2 ​ ln ( 2 ) ​ = T 1/2 ​ 0.693 ​

Biological Half-Life ( T b T_b T b ​ ) : The time required for the biological organism to eliminate 50 % 50\% 50% of an administered substance via metabolic excretion (urine, feces, sweat).

Effective Half-Life ( T e T_e T e ​ ) : The actual time required for the internal radioactivity in a patient to drop by 50 % 50\% 50% , combining physical decay and biological clearance: 1 T e = 1 T p + 1 T b ⟹ T e = T p × T b T p + T b \frac{1}{T_e} = \frac{1}{T_p} + \frac{1}{T_b} \implies T_e = \frac{T_p \times T_b}{T_p + T_b} T e ​ 1 ​ = T p ​ 1 ​ + T b ​ 1 ​ ⟹ T e ​ = T p ​ + T b ​ T p ​ × T b ​ ​ Note : The effective half-life ( T e T_e T e ​ ) is always shorter than either the physical half-life ( T p T_p T p ​ ) or biological half-life ( T b T_b T b ​ ) alone.

  • Technetium-99m Properties & The Mo-99 Generator
  • 1. Physical Properties of Technetium-99m ( 99 m Tc ^{99m}\text{Tc} 99 m Tc )

Technetium-99m is the workhorse of modern diagnostic nuclear medicine, accounting for over 85 % 85\% 85% of all clinical diagnostic studies worldwide. Its dominance is due to ideal physical characteristics:

Ideal Gamma Energy ( 140 keV 140 \ \text{keV} 140 keV ) : High enough to readily penetrate soft tissue and exit the patient's body, but low enough to be efficiently stopped and absorbed by relatively thin ( 3 / 8 inch 3/8 \ \text{inch} 3/8 inch ) Sodium Iodide NaI(Tl) \text{NaI(Tl)} NaI(Tl) scintillation crystals with high spatial resolution.

Pure Gamma Emitter : Decays via isomeric transition ( 98.6 % 98.6\% 98.6% ) without emitting damaging alpha or beta particles, keeping patient absorbed dose minimal.

Optimal Physical Half-Life ( 6.01 hours 6.01 \ \text{hours} 6.01 hours ) : Long enough to complete complex multi-hour radiopharmaceutical preparation and patient imaging procedures, but short enough to decay rapidly, minimizing patient radiation exposure.

Versatile Synthetic Chemistry : As a transition metal ( Z = 43 Z=43 Z = 43 ), technetium can exist in oxidation states from − 1 -1 − 1 to + 7 +7 + 7 , allowing it to bind to a wide variety of chemical chelates to target specific organs.

2. Molybdenum-99 / Technetium-99m Generator ("Moly Cow")

Because 99 m Tc ^{99m}\text{Tc} 99 m Tc has a short half-life of 6 hours, storing pre-made inventory is impractical. Instead, hospitals utilize a radionuclide generator system on site. +-------------------------------------------------------------------------+

  • | Mo-99 / Tc-99m GENERATOR ("MOLY COW") |
  • +-------------------------------------------------------------------------+
  • | [ Sterile Saline Vial (0.9% NaCl) ] -> Eluent Inlet |
  • | |
  • | +-----------------------------------------+ |
  • | | Lead / Depleted Uranium Shielding | |
  • | | | |
  • | | +-----------------------------+ | |
  • | | | Alumina Column (Al2O3) | | |
  • | | | Mo-99 adsorbed as MoO4(2-) | | |
  • | | +-----------------------------+ | |
  • | | | | |
  • | | Mo-99 (T1/2 = 66 h) | |
  • | | | (Beta decay 87%) | |
  • | | v | |
  • | | Tc-99m (T1/2 = 6.01 h) | |
  • | | (Forms TcO4- pertechnetate) | |
  • | +-----------------------------------------+ |
  • | | |
  • | v |
  • | [ Evacuated Collection Vial ] -> Eluates Sodium Pertechnetate (NaTcO4) |
  • +-------------------------------------------------------------------------+

Parent & Daughter Kinetics : Parent radionuclide Molybdenum-99 ( 99 Mo ^{99}\text{Mo} 99 Mo , T 1 / 2 = 66 hours T_{1/2} = 66 \ \text{hours} T 1/2 ​ = 66 hours ) is produced in a nuclear reactor by fission of Uranium-235 ( 235 U ^{235}\text{U} 235 U ). 99 Mo ^{99}\text{Mo} 99 Mo decays via β − \beta^- β − emission ( 87 % 87\% 87% ) into daughter Technetium-99m ( 99 m Tc ^{99m}\text{Tc} 99 m Tc , T 1 / 2 = 6.01 hours T_{1/2} = 6.01 \ \text{hours} T 1/2 ​ = 6.01 hours ).

Transient Equilibrium : Because the parent half-life ( 66 h 66 \ \text{h} 66 h ) is approximately 11 11 11 times longer than the daughter half-life ( 6.01 h 6.01 \ \text{h} 6.01 h ), the system achieves transient equilibrium after approximately 4 half-lives ( ∼ 23 hours \sim 23 \ \text{hours} ∼ 23 hours ). At transient equilibrium, daughter activity reaches its peak and appears to decay with the physical half-life of the parent ( 66 h 66 \ \text{h} 66 h ). Generators are typically eluted ("milked") daily at 24-hour intervals.

Column Mechanism : Anized Alumina ( Al 2 O 3 \text{Al}_2\text{O}_3 Al 2 ​ O 3 ​ , aluminum oxide) is packed inside a sterile glass column. Acidified molybdate ions ( 99 MoO 4 2 − ^{99}\text{MoO}_4^{2-} 99 MoO 4 2 − ​ ) bind tightly to the alumina column. As 99 Mo ^{99}\text{Mo} 99 Mo decays into 99 m Tc ^{99m}\text{Tc} 99 m Tc , pertechnetate ions ( 99 m TcO 4 − ^{99m}\text{TcO}_4^- 99 m TcO 4 − ​ ) are formed. Pertechnetate has a single negative charge and exhibits very low affinity for alumina.

Elution Process : Passing sterile 0.9 % 0.9\% 0.9% Normal Saline ( NaCl \text{NaCl} NaCl ) through the column washes off the loose 99 m TcO 4 − ^{99m}\text{TcO}_4^- 99 m TcO 4 − ​ , yielding Sodium Pertechnetate ( Na 99 m TcO 4 \text{Na}^{99m}\text{TcO}_4 Na 99 m TcO 4 ​ ) in the eluate, while 99 Mo ^{99}\text{Mo} 99 Mo remains tightly bound to the column.

3. Generator Quality Control (Mandatory Purity Tests)

Before administering generator eluate to patients, three mandatory quality control tests must be performed:

Radionuclidic Purity ( Mo-99 \text{Mo-99} Mo-99 Breakthrough) :

Definition : Measures the fraction of total radioactivity present as the parent radionuclide 99 Mo ^{99}\text{Mo} 99 Mo relative to 99 m Tc ^{99m}\text{Tc} 99 m Tc . Excess 99 Mo ^{99}\text{Mo} 99 Mo increases patient radiation dose significantly due to its high-energy beta emissions.

Test Method : The eluate vial is placed inside a heavy lead shield (lead pig) in a dose calibrator. The lead shield absorbs all 140 keV 140 \ \text{keV} 140 keV gamma rays from 99 m Tc ^{99m}\text{Tc} 99 m Tc , but allows high-energy 740 keV 740 \ \text{keV} 740 keV and 780 keV 780 \ \text{keV} 780 keV gamma rays from 99 Mo ^{99}\text{Mo} 99 Mo to penetrate and be measured.

USP / NRC Limit : Less than 0.15 μ Ci 0.15 \ \mu\text{Ci} 0.15 μ Ci of 99 Mo ^{99}\text{Mo} 99 Mo per 1 mCi 1 \ \text{mCi} 1 mCi of 99 m Tc ^{99m}\text{Tc} 99 m Tc (or < 0.15 kBq 99 Mo / MBq 99 m Tc <0.15 \ \text{kBq } ^{99}\text{Mo} / \text{MBq } ^{99m}\text{Tc} < 0.15 kBq 99 Mo / MBq 99 m Tc ) at the time of patient administration .

Chemical Purity (Alumina Breakthrough) :

Definition : Measures the concentration of dissolved aluminum ions ( Al 3 + \text{Al}^{3+} Al 3 + ) washed off the column into the eluate. Excess Al 3 + \text{Al}^{3+} Al 3 + causes chemical precipitation of radiopharmaceuticals (e.g., causing aggregation of 99 m Tc-MDP ^{99m}\text{Tc-MDP} 99 m Tc-MDP in the liver instead of bone).

Test Method : Colorimetric spot test using aluminon indicator paper compared against a 10 μ g/mL 10 \ \mu\text{g/mL} 10 μ g/mL aluminum standard solution.

USP Limit : Less than 10 μ g 10 \ \mu\text{g} 10 μ g of Al 3 + \text{Al}^{3+} Al 3 + per 1 mL 1 \ \text{mL} 1 mL of eluate in fission-produced generators.

Radiochemical Purity :

Definition : Measures the percentage of total 99 m Tc ^{99m}\text{Tc} 99 m Tc activity bound in the desired chemical form (e.g., bound 99 m Tc-MDP ^{99m}\text{Tc-MDP} 99 m Tc-MDP ) versus unbound free pertechnetate ( TcO 4 − \text{TcO}_4^- TcO 4 − ​ ) or hydrolyzed-reduced technetium ( TcO 2 \text{TcO}_2 TcO 2 ​ ). Unbound free pertechnetate causes non-diagnostic uptake in the stomach, thyroid gland, and salivary glands.

Test Method : Instant Thin-Layer Chromatography (ITLC).

USP Limit : Greater than 90 % to 95 % 90\% \text{ to } 95\% 90% to 95% bound radiopharmaceutical purity (depending on specific product specification).

Radiopharmaceuticals & Clinical Applications

Radiopharmaceuticals consist of two parts: a radionuclide (tag/marker emitting radiation) and a pharmaceutical vehicle (chemical complex determining biological biodistribution).

1. Key Technetium-99m Radiopharmaceuticals

99 m Tc-MDP ^{99m}\text{Tc-MDP} 99 m Tc-MDP (Methylene Diphosphonate) : Bone scintigraphy. Chemisorbs directly onto the hydroxyapatite crystal surface in areas of active osteogenesis and bone remodeling (detects metastases, fractures, osteomyelitis).

99 m Tc-Sestamibi ^{99m}\text{Tc-Sestamibi} 99 m Tc-Sestamibi (Cardiolite) / 99 m Tc-Tetrofosmin ^{99m}\text{Tc-Tetrofosmin} 99 m Tc-Tetrofosmin : Myocardial perfusion imaging (MPI) and parathyroid adenoma localization. Lipophilic cations that cross cell membranes and accumulate proportionally to blood flow within myocardial cell mitochondria.

99 m Tc-HMPAO ^{99m}\text{Tc-HMPAO} 99 m Tc-HMPAO (Exametazime) & 99 m Tc-ECD ^{99m}\text{Tc-ECD} 99 m Tc-ECD (Bicisate) : Regional cerebral blood flow (rCBF) brain perfusion imaging. Neutral lipophilic complexes that cross the blood-brain barrier and convert into hydrophilic metabolites trapped inside brain parenchyma. 99 m Tc-HMPAO ^{99m}\text{Tc-HMPAO} 99 m Tc-HMPAO is also used to label autologous leukocytes (white blood cells) for infection and occult abscess localization.

99 m Tc-MAA ^{99m}\text{Tc-MAA} 99 m Tc-MAA (Macroaggregated Albumin) : Lung perfusion imaging. Particles ( 10 to 90 μ m 10 \text{ to } 90 \ \mu\text{m} 10 to 90 μ m ) cause temporary precapillary microembolization in pulmonary capillary beds proportional to pulmonary blood flow.

99 m Tc-DTPA ^{99m}\text{Tc-DTPA} 99 m Tc-DTPA (Diethylenetriaminepentaacetic acid) : Renal glomerular filtration rate (GFR) measurement and aerosol lung ventilation imaging.

99 m Tc-MAG3 ^{99m}\text{Tc-MAG3} 99 m Tc-MAG3 (Mercaptoacetyltriglycine) : Renal tubular secretion / effective renal plasma flow (ERPF) evaluation.

99 m Tc-Sulfur Colloid ^{99m}\text{Tc-Sulfur Colloid} 99 m Tc-Sulfur Colloid : Reticuloendothelial system (RES) imaging (liver/spleen phagocytosis by Kupffer cells), lymphoscintigraphy (sentinel node mapping), and gastrointestinal transit/bleeding studies.

2. Non-Technetium Radiopharmaceuticals

Iodine-131 ( 131 I ^{131}\text{I} 131 I ) : T 1 / 2 = 8.02 days T_{1/2} = 8.02 \ \text{days} T 1/2 ​ = 8.02 days . Emits high-energy β − \beta^- β − ( 606 keV 606 \ \text{keV} 606 keV ) and primary γ \gamma γ ( 364 keV 364 \ \text{keV} 364 keV ). Used for thyroid carcinoma therapy, remnant ablation, and Graves' disease hyperthyroidism treatment (beta particles destroy thyroid tissue).

Iodine-123 ( 123 I ^{123}\text{I} 123 I ) : T 1 / 2 = 13.2 hours T_{1/2} = 13.2 \ \text{hours} T 1/2 ​ = 13.2 hours , EC decay, pure γ \gamma γ ( 159 keV 159 \ \text{keV} 159 keV ). Ideal diagnostic imaging agent for thyroid uptake scans and MIBG imaging (pheochromocytoma/neuroblastoma).

Thallium-201 ( 201 Tl ^{201}\text{Tl} 201 Tl ) : T 1 / 2 = 73 hours T_{1/2} = 73 \ \text{hours} T 1/2 ​ = 73 hours , EC decay. Emits low-energy characteristic Mercury X-rays ( 68 to 80 keV 68 \text{ to } 80 \ \text{keV} 68 to 80 keV ) and gammas ( 135 , 167 keV 135, 167 \ \text{keV} 135 , 167 keV ). Potassium analog taken up by Na + / K + \text{Na}^+/\text{K}^+ Na + / K + ATPase pump; historically used for myocardial viability.

Gallium-67 ( 67 Ga ^{67}\text{Ga} 67 Ga ) : T 1 / 2 = 78 hours T_{1/2} = 78 \ \text{hours} T 1/2 ​ = 78 hours , EC decay, multiple photopeaks ( 93 , 185 , 300 , 394 keV 93, 185, 300, 394 \ \text{keV} 93 , 185 , 300 , 394 keV ). Binds bacterial siderophores and transferrin; used for chronic inflammation, fever of unknown origin (FUO), and lymphoma evaluation.

Indium-111 ( 111 In ^{111}\text{In} 111 In ) : T 1 / 2 = 2.8 days T_{1/2} = 2.8 \ \text{days} T 1/2 ​ = 2.8 days , EC decay, photopeaks at 171 keV 171 \ \text{keV} 171 keV and 245 keV 245 \ \text{keV} 245 keV . Used for 111 In ^{111}\text{In} 111 In -DTPA cisternography and autologous leukocyte ( 111 In ^{111}\text{In} 111 In -oxine WBC) infection imaging.

Diagnostic Radioisotopes Summary

Radionuclide Physical Half-Life ( T 1 / 2 T_{1/2} T 1/2 ​ ) Primary Decay Mode & Energies Target Organ / Radiopharmaceutical Form Primary Clinical Application

99 m Tc ^{99m}\text{Tc} 99 m Tc 6.01 hours 6.01 \ \text{hours} 6.01 hours Isomeric Transition ( γ = 140 keV \gamma = 140 \ \text{keV} γ = 140 keV ) Pertechnetate, MDP, Sestamibi, HMPAO, MAA, DTPA, MAG3 Workhorse for bone, cardiac, brain, lung, renal, thyroid & RES imaging.

131 I ^{131}\text{I} 131 I 8.02 days 8.02 \ \text{days} 8.02 days Beta-minus ( β − = 606 keV \beta^- = 606 \ \text{keV} β − = 606 keV , γ = 364 keV \gamma = 364 \ \text{keV} γ = 364 keV ) Sodium Iodide ( 131 I-NaI ^{131}\text{I-NaI} 131 I-NaI ) oral solution/capsule Thyroid carcinoma therapy, thyroid ablation, Graves' disease treatment.

123 I ^{123}\text{I} 123 I 13.2 hours 13.2 \ \text{hours} 13.2 hours Electron Capture ( γ = 159 keV \gamma = 159 \ \text{keV} γ = 159 keV ) Sodium Iodide ( 123 I-NaI ^{123}\text{I-NaI} 123 I-NaI ), 123 I-MIBG ^{123}\text{I-MIBG} 123 I-MIBG Diagnostic thyroid scan/uptake, pheochromocytoma & neuroblastoma imaging.

201 Tl ^{201}\text{Tl} 201 Tl 73 hours 73 \ \text{hours} 73 hours Electron Capture (Characteristic X-rays 68 − 80 keV 68-80 \ \text{keV} 68 − 80 keV ) Thallous Chloride ( 201 Tl-TlCl ^{201}\text{Tl-TlCl} 201 Tl-TlCl ) Myocardial viability, redistribution cardiac perfusion.

67 Ga ^{67}\text{Ga} 67 Ga 78 hours 78 \ \text{hours} 78 hours Electron Capture ( γ = 93 , 185 , 300 , 394 keV \gamma = 93, 185, 300, 394 \ \text{keV} γ = 93 , 185 , 300 , 394 keV ) Gallium Citrate ( 67 Ga ^{67}\text{Ga} 67 Ga ) Chronic inflammatory lesions, fever of unknown origin (FUO), lymphoma.

111 In ^{111}\text{In} 111 In 2.8 days 2.8 \ \text{days} 2.8 days ( 67.2 h 67.2 \ \text{h} 67.2 h ) Electron Capture ( γ = 171 , 245 keV \gamma = 171, 245 \ \text{keV} γ = 171 , 245 keV ) 111 In ^{111}\text{In} 111 In -DTPA, 111 In ^{111}\text{In} 111 In -Oxine labeled WBCs CSF cisternography, acute abdominal infection & osteomyelitis localization.

Instrumentation: Anger Gamma Camera Architecture

The Anger Gamma Camera (invented by Hal Anger in 1957) is the primary stationary imaging device in nuclear medicine. It detects gamma photons emitted from the patient and reconstructs their spatial position and energy. +-------------------------------------------------------------------------+

  • | ANGER GAMMA CAMERA ARCHITECTURE |
  • +-------------------------------------------------------------------------+
  • | [ PATIENT ORGAN ] |
  • | | |
  • | Gamma Photons (140 keV) |
  • | v |
  • | +-------------------------------------------------------------------+ |
  • | | LEAD COLLIMATOR (Parallel Hole, Pinhole, etc.) | |
  • | +-------------------------------------------------------------------+ |
  • | | (Rejects oblique scatter) |
  • | v |
  • | +-------------------------------------------------------------------+ |
  • | | NaI(Tl) SCINTILLATION CRYSTAL (3/8" Thick, Emits 415 nm Light) | |
  • | +-------------------------------------------------------------------+ |
  • | | (Visible Light Photons) |
  • | v |
  • | +-------------------------------------------------------------------+ |
  • | | LIGHT GUIDE / OPTICAL COUPLING | |
  • | +-------------------------------------------------------------------+ |
  • | | |
  • | +-------------------------------------------------------------------+ |
  • | | PHOTOMULTIPLIER TUBES (PMT Array) - Photocathode -> Dynodes | |
  • | +-------------------------------------------------------------------+ |
  • | | Electrical Pulses |
  • | v |
  • | +-------------------------------------------------------------------+ |
  • | | PREAMPLIFIERS & ANGER POSITIONING LOGIC (X+, X-, Y+, Y-) | |
  • | +-------------------------------------------------------------------+ |
  • | | Z = Total Energy Pulse |
  • | v |
  • | +-------------------------------------------------------------------+ |
  • | | PULSE HEIGHT ANALYZER (PHA Window: 140 keV ± 10% / 126-154 keV) | |
  • | +-------------------------------------------------------------------+ |
  • | | Validated Photopeak Events |
  • | v |
  • | [ DIGITAL IMAGE DISPLAY ] |
  • +-------------------------------------------------------------------------+
  • 1. Lead Collimator

Function : Placed on the front face of the detector. Because gamma rays cannot be focused by optical lenses, collimators use thick lead or tungsten channels (septa) to absorb scattered or oblique gamma rays, permitting only photons traveling parallel to the hole axes to reach the crystal. The collimator defines the spatial origin of detected photons.

Collimator Types :

Parallel-Hole : Standard collimator for routine imaging. Holes are parallel to each other. Image size equals actual organ size ( 1 : 1 1:1 1 : 1 ratio).

Pinhole : Single small aperture on a cone-shaped lead body. Produces an inverted, magnified image of small organs (e.g., thyroid gland, pediatric hip joints). Resolution increases as object-to-pinhole distance decreases.

Converging : Holes slant inward toward the patient. Magnifies smaller organs to fill the crystal surface.

Diverging : Holes slant outward away from the patient. Demagnifies large organs (e.g., full lung field) to fit a small crystal.

Tradeoff : Spatial resolution is inversely proportional to sensitivity. High-Resolution (LEHR) collimators have longer, narrower holes (high resolution, lower count rate sensitivity), while High-Sensitivity collimators have shorter, wider holes.

2. Sodium Iodide Thallium-Doped NaI(Tl) \text{NaI(Tl)} NaI(Tl) Scintillation Crystal

Scintillation Mechanism : Converts absorbed high-energy gamma photons into thousands of low-energy visible light photons (scintillations at ∼ 415 nm \sim 415 \ \text{nm} ∼ 415 nm , blue light). The total light output is strictly proportional to the energy deposited by the absorbed gamma ray.

Thallium Doping ( 0.1 % 0.1\% 0.1% ) : Pure NaI is an inefficient scintillator at room temperature; thallium (Tl) creates activator color centers within the crystal lattice that dramatically increase scintillation light conversion efficiency.

Hygroscopic Nature : NaI(Tl) crystals absorb moisture from ambient air, causing yellow discoloration and clouding (ruining light transmission). Crystals must be hermetically sealed inside an airtight aluminum casing with a glass optical backplate window.

Crystal Thickness : Standard thickness is 3 / 8 inch 3/8 \ \text{inch} 3/8 inch ( 9.5 mm 9.5 \ \text{mm} 9.5 mm ) .

Thinner crystal ( 1 / 4 inch 1/4 \ \text{inch} 1/4 inch ) : Higher spatial resolution, but lower detection sensitivity for 140 keV 140 \ \text{keV} 140 keV gammas.

Thicker crystal ( 5 / 8 inch 5/8 \ \text{inch} 5/8 inch ) : Higher detection sensitivity for high-energy gammas (e.g., 364 keV 364 \ \text{keV} 364 keV of 131 I ^{131}\text{I} 131 I ), but lower spatial resolution due to increased light spreading.

3. Light Guide & Photomultiplier Tube (PMT) Array

An array of 37 to 91 37 \text{ to } 91 37 to 91 hexagonal or square PMTs is optically coupled to the rear glass window of the crystal via clear optical grease or light guides.

PMT Function : Converts visible scintillation light photons into an electrical current. Light strikes the photocathode to emit photoelectrons (photoelectric effect), which are accelerated through a series of 10 to 14 10 \text{ to } 14 10 to 14 dynodes , multiplying the electron signal by 10 6 to 10 8 10^6 \text{ to } 10^8 1 0 6 to 1 0 8 (high current gain).

4. Anger Positioning Logic & Pulse Height Analyzer (PHA)

Spatial Positioning Logic : Signal amplitudes from surrounding PMTs are combined in an Anger resistor network to calculate spatial coordinates ( X + , X − , Y + , Y − X^+, X^-, Y^+, Y^- X + , X − , Y + , Y − ) of the scintillation event on the crystal face: X = X + − X − X + + X − , Y = Y + − Y − Y + + Y − X = \frac{X^+ - X^-}{X^+ + X^-}, \quad Y = \frac{Y^+ - Y^-}{Y^+ + Y^-} X = X + + X − X + − X − ​ , Y = Y + + Y − Y + − Y − ​

Total Energy Signal ( Z Z Z ) : Summing signals from all PMTs yields total pulse height Z Z Z , which represents the total energy deposited in the crystal ( Z = X + + X − + Y + + Y − Z = X^+ + X^- + Y^+ + Y^- Z = X + + X − + Y + + Y − ).

Pulse Height Analyzer (PHA) : Filters incoming pulses by energy. Compton-scattered gamma photons lose energy inside the patient body and emerge with lower energies ( < 140 keV <140 \ \text{keV} < 140 keV ). If scattered photons were imaged, they would degrade image contrast and spatial resolution. The PHA establishes an energy window centered on the photopeak:

For 99 m Tc ^{99m}\text{Tc} 99 m Tc ( 140 keV 140 \ \text{keV} 140 keV ), a standard 20 % 20\% 20% energy window ( 140 keV ± 10 % 140 \ \text{keV} \pm 10\% 140 keV ± 10% ) accepts only energy pulses between 126 keV 126 \ \text{keV} 126 keV and 154 keV 154 \ \text{keV} 154 keV , rejecting lower-energy Compton scatter.

  • SPECT & SPECT/CT Hybrid Imaging
  • 1. Single Photon Emission Computed Tomography (SPECT)

Conventional 2D planar scintigraphy suffers from overlapping tissue structures. SPECT utilizes one, two, or three gamma camera heads mounted on a rotating gantry that orbit 360 ∘ 360^\circ 36 0 ∘ around the patient (or 180 ∘ 180^\circ 18 0 ∘ for cardiac imaging), acquiring multiple 2D projection angles (typically 64 to 128 64 \text{ to } 128 64 to 128 projections over 360 ∘ 360^\circ 36 0 ∘ ).

Tomographic Reconstruction : Projection data are processed using Filtered Backprojection (FBP) or Ordered Subsets Expectation Maximization (OSEM) iterative reconstruction algorithms to generate 3D volumetric datasets displayed as cross-sectional axial, coronal, and sagittal slices.

2. Hybrid SPECT/CT Imaging

Hybrid SPECT/CT systems integrate a dual-head SPECT gamma camera and a multi-slice CT scanner mounted in tandem on a single gantry with a shared patient couch.

Dual Advantages :

Anatomical Coregistration : Overlays low-resolution functional SPECT molecular/metabolic data precisely onto high-resolution CT anatomical cross-sections (fused images), allowing exact localization of lesions (e.g., distinguishing bone metastases from degenerative joint disease).

CT-Based Attenuation Correction (CT-AC) : Deep tissue organs attenuate emitted gamma photons. SPECT/CT uses CT Hounsfield unit attenuation maps converted to 140 keV 140 \ \text{keV} 140 keV linear attenuation coefficients ( μ \mu μ ) to correct for photon absorption across varying tissue densities (lung, muscle, bone), producing accurate quantitative image reconstruction.